The first ever Biotechnology IPO Monitor has been published by technology researchers Library House. Aimed at investors, the report, produced in association with Ernst & Young, is an annual review of the current status of advanced stage private biotech companies in the UK, and includes an updated online monitoring service.
The review includes 29 UK biotech companies assessed to be potential IPO candidates in the coming 12 to 18 months, with one, Ark Therapeutic, already having already floated in March 2004.
David Chiswell, founder and former CEO of Cambridge Antibody Technology, said: “Raising capital on the public markets remains a hard task for biotechnology companies. Often in a pre-profitable state, they do not comply with the IPO norm, despite frequently being on the verge of major breakthroughs. Any tool which measures the success factors and therefore predicts the potential of these companies will be invaluable to these companies as well as to the marketplace going forward.”
The information is derived from Library House’s own database, which measures biotech companies from initial investment to final preparation for IPO or trade sale.